GRIFOLS CL. A

Grifols has begun treating the first patients in two separate phase-3 studies to broaden US approvals for the immunoglobulin products GAMUNEX-C (SIGMA study) and XEMBIFY (XPERT study). SIGMA is evaluating GAMUNEX-C in secondary immunodeficiency following blood cancers (50 participants) with the aim of reducing the rate of serious bacterial infections. XPERT is comparing XEMBIFY with GAMUNEX-C in CIDP patients (about 40 patients across 20 sites) to demonstrate noninferiority; XEMBIFY sales rose by almost 60% in 2025. In addition, a third EXCELL study is ongoing to prevent infections in hypogammaglobulinemic patients. » More on de.investing.com

Grifols reported Q1 2026 earnings per share of $0.1731 (7.99% above the forecast of $0.1603), while revenue of $2.0 billion missed the expected $2.06 billion by 2.91%. The stock fell intraday to $8.10 and declined further in after-hours trading to $7.56. Growth was driven by the biopharma division, notably the IG franchise; the diagnostics segment suffered from the dissolution of a joint venture. Grifols confirms its full-year guidance and is focusing on expanding its plasma network and integrating Biotest products to support future growth. » More on de.investing.com

Grifols reported Q1 2026 earnings per share of $0.1613, slightly above expectations, while revenue of $2 billion missed forecasts and the stock fell sharply. Currency movements (EUR/USD increase) weighed on reported revenue and EBITDA; on a constant-currency basis revenue rose 3.3% and adjusted EBITDA 0.8%. The performance was driven by the biopharma segment, notably the immunoglobulin business with double‑digit growth, while diagnostics and bio‑supplies weakened. Grifols confirmed its 2026 targets, reported successful refinancings, plans to expand plasma sourcing outside the US (including Egypt), and is reviewing a potential IPO of its US biopharma business. » More on de.investing.com